Neonatal Outcomes Following Selective Serotonin Reuptake Inhibitor Use During Pregnancy - Takeaways - MDSpire

Neonatal Outcomes Following Selective Serotonin Reuptake Inhibitor Use During Pregnancy

  • By

  • Layla Aref

  • Jacob J. Hughey

  • Sherwin Shirazi

  • Jennifer M. S. Sucre

  • Lisa Bastarache

  • July 13, 2026

Share

  • 1

    Approximately 26% of women will experience depression in their lifetime, leading to SSRI prescriptions during pregnancy.

  • 2

    SSRIs can cross the placenta, raising concerns about potential adverse neonatal health effects.

  • 3

    Conducting RCTs during pregnancy is ethically challenging, leading to reliance on retrospective observational studies.

  • 4

    The study utilized a target trial framework to analyze neonatal outcomes linked to SSRI exposure during pregnancy.

  • 5

    The cohort included 77,813 mother-baby dyads from Vanderbilt University Medical Center, covering pregnancies from 2006 to 2022.

Original Source(s)

Neonatal Outcomes Following Selective Serotonin Reuptake Inhibitor Use During Pregnancy

  • by Layla Aref, Jacob J. Hughey, Sherwin Shirazi, Jennifer M. S. Sucre, Lisa Bastarache

  • July 13, 2026

Related Content

Survival beyond treatment: patterns and determinants of disease-free survival in cervical cancer at a tertiary care center in India

Interventional radiology in the management of vascular complications in urogynecology: a lower-extremity hematoma after transobturator sling—case report

Retraction Note: Laparoscopic ventral rectopexy plus sacral colpopexy: continuous locked suture for mesh fixation. A randomized clinical trial